Gender differences in the treatment of first-episode schizophrenia: Results from the European First Episode Schizophrenia Trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F15%3A00085824" target="_blank" >RIV/00216224:14740/15:00085824 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/65269705:_____/15:00063779 RIV/00179906:_____/15:10313894 RIV/00843989:_____/15:E0104984

Výsledek na webu

<a href="http://ac.els-cdn.com/S092099641530013X/1-s2.0-S092099641530013X-main.pdf?_tid=da3edb18-b849-11e5-871b-00000aacb35d&acdnat=1452506483_b9f6dee7c1c1b3be1898aeef6e36aeac" target="_blank" >http://ac.els-cdn.com/S092099641530013X/1-s2.0-S092099641530013X-main.pdf?_tid=da3edb18-b849-11e5-871b-00000aacb35d&acdnat=1452506483_b9f6dee7c1c1b3be1898aeef6e36aeac</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.schres.2015.10.013" target="_blank" >10.1016/j.schres.2015.10.013</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Gender differences in the treatment of first-episode schizophrenia: Results from the European First Episode Schizophrenia Trial

Popis výsledku v původním jazyce

Gender differences in the response to antipsychotic treatment have been detected in the past, but not studied in great detail. The results of the European First-Episode Schizophrenia Trial (EUFEST) were analyzed with a focus on gender differences in theresponse to randomized treatment of first-episode schizophrenia. A total of 498 patients (298 men and 200 women) were randomly assigned by a web-based online system to open-label treatment with haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone. Treatment response was evaluated using the positive and negative syndrome scale (PANSS). Data were collected at baseline and then prospectively for one year. Baseline characteristics (age and proportion of patients assigned to individual antipsychotics) were the same between the male and female patients with the exception of ziprasidone: significantly fewer men, proportionately, were prescribed ziprasidone.

Název v anglickém jazyce

Gender differences in the treatment of first-episode schizophrenia: Results from the European First Episode Schizophrenia Trial

Popis výsledku anglicky

Gender differences in the response to antipsychotic treatment have been detected in the past, but not studied in great detail. The results of the European First-Episode Schizophrenia Trial (EUFEST) were analyzed with a focus on gender differences in theresponse to randomized treatment of first-episode schizophrenia. A total of 498 patients (298 men and 200 women) were randomly assigned by a web-based online system to open-label treatment with haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone. Treatment response was evaluated using the positive and negative syndrome scale (PANSS). Data were collected at baseline and then prospectively for one year. Baseline characteristics (age and proportion of patients assigned to individual antipsychotics) were the same between the male and female patients with the exception of ziprasidone: significantly fewer men, proportionately, were prescribed ziprasidone.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FL - Psychiatrie, sexuologie

OECD FORD obor

—

Projekt

<a href="/cs/project/ED1.1.00%2F02.0068" target="_blank" >ED1.1.00/02.0068: CEITEC - central european institute of technology</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Schizophrenia Research

ISSN

0920-9964

e-ISSN

—

Svazek periodika

169

Číslo periodika v rámci svazku

1-3

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

5

Strana od-do

303-307

Kód UT WoS článku

000366458600046

EID výsledku v databázi Scopus

—